Want to see SE:MAGLE full AI Analyst Report?
Top Page
Magle Chemoswed Holding AB
(MAGLE)
Select Model
Select Model
Rating:48Neutral
Price Target:
kr0.56
▼(-96.75% Downside)
Action:Reiterated
Date:09/30/26
The score is held down primarily by weak financial performance: large losses, significant cash burn, and rising leverage. Technical indicators are mixed but somewhat supportive near term (price above 20D/50D with positive MACD), while valuation remains constrained by negative earnings and no provided dividend yield.
Positive Factors
CDMO platform
The company’s CDMO platform serves regulated pharmaceutical and biotech customers through development, analytical, API, and finished-dose production services. This diversified technical offering can support recurring customer relationships and creates a durable base for project and manufacturing revenue.
Negative Factors
Deep losses
Severe TTM losses show that the current cost structure is overwhelming gross profit, weakening the durability of earnings even while revenue grows. Persistently negative operating performance could constrain reinvestment, reduce financial resilience, and make a return to profitability dependent on substantial execution improvements.
Read all positive and negative factors
Positive Factors
Negative Factors
CDMO platform
The company’s CDMO platform serves regulated pharmaceutical and biotech customers through development, analytical, API, and finished-dose production services. This diversified technical offering can support recurring customer relationships and creates a durable base for project and manufacturing revenue.
Read all positive factors
Magle Chemoswed Holding AB (MAGLE) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr75.08M
Dividend Yield1.17%
Average Volume (3M)242.18K
Price to Earnings (P/E)―
Beta (1Y)0.15
Revenue Growth1.80%
EPS Growth-1367.42%
CountrySE
Employees150
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-8.23
Shares Outstanding155,117,800
10 Day Avg. Volume679,548
30 Day Avg. Volume242,175
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.92
Price to Sales (P/S)1.28
P/FCF Ratio-8.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.4
Revenue Forecast (FY)kr285.10M
Magle Chemoswed Holding AB Business Overview & Revenue Model
Company Description
Magle Chemoswed Holding AB (publ), based in Malmö, Sweden, specializes in the research, development, and manufacturing of products within the pharmaceutical chemistry and technology sectors. The company's core activities include the process develo...
How the Company Makes Money
Magle Chemoswed Holding AB primarily makes money by selling contract services to pharmaceutical and biotech customers, where it is paid for development and manufacturing work delivered under customer agreements. Key revenue streams include (1) con...
Magle Chemoswed Holding AB Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
38
Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 290.72M | 282.92M | 236.04M | 170.44M | 145.68M | 132.15M |
| Gross Profit | 246.01M | 232.43M | 221.55M | 152.87M | 134.38M | 110.83M |
| EBITDA | -31.06M | -24.25M | 59.21M | 31.40M | 25.77M | 18.14M |
| Net Income | -169.90M | -159.88M | 11.94M | 12.17M | 9.14M | 4.28M |
Balance Sheet | ||||||
| Total Assets | 813.22M | 911.03M | 1.09B | 272.97M | 252.86M | 237.18M |
| Cash, Cash Equivalents and Short-Term Investments | 2.08M | 13.59M | 2.72M | 7.08M | 9.88M | 3.98M |
| Total Debt | 343.99M | 346.19M | 359.92M | 60.30M | 50.34M | 36.46M |
| Total Liabilities | 552.80M | 515.19M | 531.58M | 114.75M | 106.09M | 98.39M |
| Stockholders Equity | 260.41M | 395.84M | 560.60M | 158.22M | 146.77M | 138.79M |
Cash Flow | ||||||
| Free Cash Flow | -111.10M | -44.52M | -27.85M | 209.00K | -4.41M | 14.21M |
| Operating Cash Flow | -109.79M | -31.93M | -11.70M | 15.33M | 12.47M | 26.04M |
| Investing Cash Flow | -1.47M | -12.59M | -9.97M | -20.41M | -21.49M | -34.05M |
| Financing Cash Flow | 107.32M | 55.45M | 17.09M | 2.52M | 14.80M | 5.87M |
Magle Chemoswed Holding AB Technical Analysis
Negative
17.20
Price Trends
0.49
Negative
1.24
Negative
5.34
Negative
Market Momentum
0.02
Positive
47.71
Neutral
5.14
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:MAGLE, the sentiment is Negative. The current price of 17.2 is above the 20-day moving average (MA) of 0.54, above the 50-day MA of 0.49, and above the 200-day MA of 5.34, indicating a bearish trend. The MACD of 0.02 indicates Positive momentum. The RSI at 47.71 is Neutral, neither overbought nor oversold. The STOCH value of 5.14 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:MAGLE.
Magle Chemoswed Holding AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | kr397.26M | 2.07 | 63.09% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | kr75.08M | -0.06 | -46.30% | 1.17% | 1.80% | -1367.42% | |
48 Neutral | kr190.53M | -8.07 | -56.09% | ― | ― | 14.10% | |
48 Neutral | kr79.04M | -2.10 | -106.23% | ― | -97.37% | 25.28% | |
45 Neutral | kr71.04M | -14.45 | -190.99% | ― | 22.42% | 30.55% | |
43 Neutral | kr1.51B | -3.03 | -99.58% | ― | -87.22% | -70.29% |
* Healthcare Sector Average
SE:MAGLE
Magle Chemoswed Holding AB
0.48
-18.52
-97.45%
SE:BINV
BioInvent International AB
22.90
-5.40
-19.08%
SE:NEEMS.B
Scandinavian ChemoTech AB Class B
2.71
-2.31
-46.02%
SE:ELIC
Elicera Therapeutics AB
2.86
-3.92
-57.83%
SE:SPAGO
Spago Nanomedical AB
0.10
-0.03
-20.80%
SE:CANTA
Cantargia AB
1.41
-1.38
-49.41%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.